CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Blood collection on their first consultation and 10 to 14 days laterWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug599 Cognitive behavioral therapy (CBT) Wiki 1.00
drug2783 computerized cognitive training (CCT) Wiki 1.00
drug371 Blood collection on admission and longitudinally Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D001008 Anxiety Disorders NIH 0.17

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Identification of Predictive Immune Biomarkers Based on the Understanding of COVID-19 Pathogenesis to Influence Therapeutic Management

The spectrum of the COVID-19 disease ranges from benign to asymptomatic to viral pneumopathy that can progress to acute respiratory distress syndrome (ARDS). The host-pathogen relationships and the physiopathological mechanisms underlying the clinical aggravation of COVID-19 patients remain misunderstood. The project aim is to create a prospective cohort of biological samples collected from well characterized COVID-19 patients. This project aims first to identify based on these samples an early immune signature predictive of clinical worsening of COVID-19 patients in order to improve their management, and secondarily to better understand pathophysiological mechanisms underlying the different phases of the disease in order to identify innovative therapeutic targets and vaccine perspectives.

NCT04385108 COVID-19 Biological: Blood collection on admission and longitudinally Biological: Blood collection on their first consultation and 10 to 14 days later

Primary Outcomes

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor fluorescence-activated cell sorter (FACS) analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 0

Description: Analysis on plasma samples of a wide range of cytokines and chemokines using multiplex

Measure: Dosage of cytokines and chemokines in plasma samples

Time: Day 0

Secondary Outcomes

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 2

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 4

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 8

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 12

Description: Analysis of the phenotypic profiling of blood T-cells by multicolor FACS analysis assessing T cell subsets through the expression of a wide range of surface and intracellular markers

Measure: Immune signature

Time: Day 30 (or in discharge)

Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin

Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity

Time: Day 0

Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin

Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity

Time: Day 2

Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin

Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity

Time: Day 4

Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin

Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity

Time: Day 8

Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin

Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity

Time: Day 12

Description: Measurement of SARS-CoV-2 specific Immunoglobulin M, Immunoglobulin G and Immunoglobulin

Measure: Analysis of the early dynamics of SARS-CoV-2-specific humoral immunity

Time: Day 30 (or in discharge)


No related HPO nodes (Using clinical trials)